Method of regulating angiogenesis unsing ryk protein
CA 2408349 A1 · Owner: Bayer Corporation · Inventors: Dubois-Stringfellow, Nathalie A.; Roczniak, Steve; Zolotorev, Alya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Ryk protein was found to have a novel activity in regulating angiogenesis. New variant Ryk proteins were constructed that were useful in modulating the capillary forming activity of endothelial cells. Variant Ryk proteins may be , employed as therapeutics in diseases such as cancer wound healing, diabetic , retinopathies macular degeneration, and cardiovascular diseases and other , diseases or clinical conditions where angiogenesis is relevant to the causation or treatment of the disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 9, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.